Medical Research

MICHAEL J FOX FOUNDATION FOR PARKINSONS RESEARCH

aka MJFF

New York, NY

Mission

The Michael J. Fox Foundation was launched in 2000 and directs funds to promising research opportunities worldwide. The Foundation strives to make every dollar count as it seeks a cure for Parkinson's disease. With growing resources, the Foundation's focus is increasingly on the clinical and translational research crucial to making strides toward a cure and improved therapies for those living with Parkinson's today. Michael J. Fox was diagnosed with young-onset Parkinson's disease in 1991. Armed with the knowledge that with proper funding, a cure for Parkinson's disease was within reach, Fox publicly disclosed his condition in 1998 and committed himself to the campaign for increased Parkinson's awareness and research funding.

Ruling Year

2000

Principal Officer

Todd Sherer

Main Address

Grand Central Station PO Box 4777

New York, NY 10163 USA

Keywords

Parkinson's disease, scientific research, preventing Parkinson's

EIN

13-4141945

 Number

6913658750

Cause Area (NTEE Code)

Fund Raising and/or Fund Distribution (H12)

Specifically Named Diseases Research (H80)

Brain Disorders (H48)

IRS Filing Requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Sign in or create an account to view Form(s) 990 for 2018, 2017 and 2016.
Register now

Programs + Results

What we aim to solve

Parkinson’s disease (PD) affects nearly 1 million people in the United States and more than 6 million people worldwide, a figure estimated to double by 2040 as the population ages and becomes at increasing risk for neurologic disorders. PD occurs when brain cells that make dopamine, a chemical that coordinates movement, stop working or die. Parkinson’s is a “movement disorder” and can result in symptoms of tremor, slowness, stiffness, walking and balance problems, as well as mood disorders and cognitive impairment. PD is a lifelong and progressive disease, which means that symptoms slowly worsen over time. There is no known cure and the need for new Parkinson’s treatments has never been more critical. The Michael J. Fox Foundation for Parkinson’s Disease works tirelessly every day with one urgent goal in mind: to find a cure for Parkinson’s and close our doors.

Our programs

What are the organization's current programs, how do they measure success, and who do the programs serve?

SOURCE: Self-reported by organization

Funding for Parkinson's Disease Research

Where we work

Our Results

How does this organization measure their results? It's a hard question but an important one. These quantitative program results are self-reported by the organization, illustrating their committment to transparency, learning, and interest in helping the whole sector learn and grow.

SOURCE: Self-reported by organization

Total New Funding Deployed to speeding Parkinson's Disease Drug Development by Year (Program Expense Total)

TOTALS BY YEAR
Population(s) served

General/Unspecified

Related program

Funding for Parkinson's Disease Research

Type of Metric

Output - describing our activities and reach

Direction of Success

Increasing

Context notes

Numbers reflect USD

Number of New Research Grants Funded by Year (US and Non-US)

TOTALS BY YEAR
Population(s) served

General/Unspecified

Type of Metric

Output - describing our activities and reach

Direction of Success

Increasing

Charting Impact

Five powerful questions that require reflection about what really matters - results.

SOURCE: Self-reported by organization

What is the organization aiming to accomplish?

What are the organization's key strategies for making this happen?

What are the organization's capabilities for doing this?

How will they know if they are making progress?

What have they accomplished so far and what's next?

Founded in 2000, The Michael J. Fox Foundation (MJFF) is dedicated to finding a cure for Parkinson's disease through an aggressively funded research agenda and ensuring the development of improved therapies for those living with Parkinson's. From inception, MJFF has worked to jolt Parkinson’s drug development out of a standstill. Our activities go beyond funding basic research discoveries. We identify and fund innovative ideas in PD discovery (vetting over 600 Parkinson’s drug targets and supporting more than 125 clinical trials to date), including high-risk, high-reward opportunities; an approach that in less than two decades has transformed the broader approach in the Parkinson’s research field. We laser-focus on the drug targets that show real potential to help people, and proactively chaperone them along the complicated pipeline toward clinical trials. At the same time, the Foundation puts building blocks in place to increase the odds of clear, actionable results from those trials.

To get just one new drug from the lab to pharmacy shelves can take decades, billions of dollars and thousands of research volunteers. MJFF’s on-staff research team prioritizes research projects, gains stakeholder buy-in, and provides funding and technical assistance to push them forward. Our expertise in science and the business of science helps us solve systemic challenges standing in the way of progress and lets us target resources where they are needed most — to pay off for patients faster. We: • Review nearly 1,000 grant proposals annually and fund millions in grants globally. • Assemble Parkinson’s researchers worldwide to participate in our consortia, assess and review grants, and make use of our open-access data and research tools. • Sponsor game changing, landmark clinical PD studies that offer open-access data for the wider research community. • Mobilize patients and families to get involved in research, and develop platforms that provide accessible entry points.

Critical investments are made possible by the urgent optimism and actions of a passionate Parkinson’s community. In 2017, nearly 100,000 donors generously contributed to our mission, helping fund $98 million in research programs; $10 million of which came from 5,800 Team Fox members who make up MJFF’s grassroots fundraising community. MJFF works hard to maximize every dollar to drive science with the greatest potential to benefit people with PD. Since inception, 88 cents of every dollar we spend goes direct to high-impact research programs — with more than $800 million in total research funded to date. We hold no endowment or excess financial reserves, deploying funds as quickly as possible for immediate impact. Our in-house team of formally trained PhD and MD neuroscientists and project managers work closely with peer reviewers to make funding decisions, direct research goals and troubleshoot issues. Today, this team oversees a research portfolio of approximately 600 active grants.

The PD drug development pipeline is abuzz with activity and investment toward new treatments. In 2006, the Foundation announced its first dedicated funding stream to bring more biotech and pharmaceutical research groups into the Parkinson’s field; today, deeply resourced Parkinson’s programs are under way at nearly every major company. In 2009, no organized effort existed to pursue a PD biomarker — an objective measure and critical missing link in the search for better treatments. Today, MJFF’s landmark study, the Parkinson’s Progression Markers Initiative (PPMI) has set the standard for the collection and sharing of rigorously standardized data. Parkinson’s families are shaping the future of PD research. • More than 81,000 volunteers are registered with Fox Trial Finder, MJFF’s clinical trial matching tool. • More than 27,000 people are enrolled in MJFF’s Fox Insight online study. • A growing social network of 1 million+ are engaging with MJFF and each other on our way to the cure.

MJFF’s world-class research program is focused on chaperoning promising ideas from whatever step they are in to the next step and ultimately to the investors who can get them to patients. Multiple experimental treatments selected for early on support by MJFF have garnered significant follow-on funding and moved to the later stages of research (including clinical testing). Today, multiple therapies are in Phase III testing or filing for FDA approval. Research into disease-modifying therapies - that can delay, prevent or reverse PD - is a top priority for MJFF. We are deepening our impact in the field as a leading convener. Representing patients at every turn, we understand the research process and are a partner to drug developers and trial sponsors. To move us all closer to the goal line, we continue to spearhead pre-competitive consortia to advance research, amplify the patient voice, and lead conversations with regulators to outline paths for therapeutic assessment.

External Reviews

Financials

MICHAEL J FOX FOUNDATION FOR PARKINSONS RESEARCH

Need more info on this nonprofit?

Need more info on this nonprofit?

FREE: Gain immediate access to the following:

  • Address, phone, website and contact information
  • Forms 990 for 2018, 2017 and 2016
  • A Pro report is also available for this organization.

See what's included

Operations

The people, governance practices, and partners that make the organization tick.

Need more info?

FREE: Gain immediate access to the following:

  • Address, phone, website and contact information
  • Forms 990 for 2018, 2017 and 2016
  • A Pro report is also available for this organization.

See what's included

Board Leadership Practices

GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section, which enables organizations and donors to transparently share information about essential board leadership practices.

SOURCE: Self-reported by organization

BOARD ORIENTATION & EDUCATION

Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations?

No

CEO OVERSIGHT

Has the board conducted a formal, written assessment of the chief executive within the past year?

No

ETHICS & TRANSPARENCY

Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year?

No

BOARD COMPOSITION

Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership?

No

BOARD PERFORMANCE

Has the board conducted a formal, written self-assessment of its performance within the past three years?

No